产品
编 号：F113539
分子式：C44H56N8O9
分子量：840.96
分子式：C44H56N8O9
分子量：840.96
产品类型
规格
价格
是否有货
1mg
询价
询价
5mg
询价
询价
结构图
CAS No: 130408-77-4
产品详情
生物活性：
A71623, a CCK-4-based peptide, is a potent and highly selective CCK-A full agonist. The IC50s for A-71623 are 3.7 nM in guinea pig pancreas (CCK-A) and 4500 nM in cerebral cortex (CCK-B) in radioligand binding assays, respectively.
体内研究：
A71623 (A-63387; i.c.v., but not i.p., injections) reduces food intakes and suppresses intakes of a liquid diet in both deprived and sated rats. A71623 dampens Purkinje neuron pathology and associates deficits in motor performance in Pcp2-ATXN1[30Q]D776;Cck-/- and Pcp2-AXTN1[82Q] mice. A71623 improves motor performance of Pcp2-ATXN2[127Q] SCA2 mice.Animal Model:Adult male, Sprague-Dawley rats
Dosage:5 μL
Administration:Intracerebroventricular (i.c.v) administration, A-71623 was infused using a 28 gauge injection cannula in a volume of 5uL over 60 s
Result:Reduced food intakes and suppressed intakes of a liquid diet.
Animal Model:ATXN1[30Q]-D776, ATXN1[82Q]-D776, ATXN2[127Q], and WT/FVB/NJ mice
Dosage:0.02 mg/kg/day
Administration:Osmotic minipumps containing either A71623 (0.02mg/kg/day) were implanted intraperitoneally (i.p.)
Result:Treatment dampened Purkinje neuron pathology in ATXN1[30Q]D776;Cck-/- mice and ATXN1[82Q] mice.Improved motor performance in ATXN2[127Q] mice.
体外研究：
In guinea pig gastric glands, the affinities of A-71623 for the cholecystokinin (CCK)-B/gastrin receptor were 11 μM.
A71623, a CCK-4-based peptide, is a potent and highly selective CCK-A full agonist. The IC50s for A-71623 are 3.7 nM in guinea pig pancreas (CCK-A) and 4500 nM in cerebral cortex (CCK-B) in radioligand binding assays, respectively.
体内研究：
A71623 (A-63387; i.c.v., but not i.p., injections) reduces food intakes and suppresses intakes of a liquid diet in both deprived and sated rats. A71623 dampens Purkinje neuron pathology and associates deficits in motor performance in Pcp2-ATXN1[30Q]D776;Cck-/- and Pcp2-AXTN1[82Q] mice. A71623 improves motor performance of Pcp2-ATXN2[127Q] SCA2 mice.Animal Model:Adult male, Sprague-Dawley rats
Dosage:5 μL
Administration:Intracerebroventricular (i.c.v) administration, A-71623 was infused using a 28 gauge injection cannula in a volume of 5uL over 60 s
Result:Reduced food intakes and suppressed intakes of a liquid diet.
Animal Model:ATXN1[30Q]-D776, ATXN1[82Q]-D776, ATXN2[127Q], and WT/FVB/NJ mice
Dosage:0.02 mg/kg/day
Administration:Osmotic minipumps containing either A71623 (0.02mg/kg/day) were implanted intraperitoneally (i.p.)
Result:Treatment dampened Purkinje neuron pathology in ATXN1[30Q]D776;Cck-/- mice and ATXN1[82Q] mice.Improved motor performance in ATXN2[127Q] mice.
体外研究：
In guinea pig gastric glands, the affinities of A-71623 for the cholecystokinin (CCK)-B/gastrin receptor were 11 μM.
产品资料
Copyright©2015-2024 沪ICP备2022026524号-1
沪公网安备